Merck’s Keytruda doesn’t meet goals in bladder cancer study

Merck’s Keytruda doesn’t meet goals in bladder cancer study

Merck Inc. said late Tuesday that its drug Keytruda did not reach its goals in a late-stage clinical study for the treatment of bladder cancer. The drug maker said bladder cancer patients given Keytruda in a Phase 3 clinical study did not show a statistically significant improvement in overall survival or progression-free survival compared with patients given standard chemotherapy. Keytruda is already approved to treat several other types of cancer. In 2019, Merck reported Keytruda sales made up $11.08 billion of its $46.84 billion in sales. Merck shares rose 0.3% after hours, following a 0.7% decline to close the regular session at $82.26.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.